This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,481,760 to Emory University to study how methamphetamine (MA) use impacts immune dysfunction in people living with HIV (PWH) on antiretroviral therapy (ART). The 5-year award will leverage existing longitudinal blood samples and collect new blood and cerebrospinal fluid samples to investigate a multi-step process by which MA promotes...
This Project Grant award of $1,408,665 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to elucidate the mechanisms by which the drug metformin regulates T cell metabolism and function in the context of obesity. The key objectives are to: (1) identify changes in gut microbiome and inflammatory cytokines in obese mice treated with metformin and determine if these...
This Project Grant award of $2,331,737 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a comprehensive study to investigate the impact of methamphetamine (MA) use on HIV persistence, immune dysfunction, and clinical outcomes among people living with HIV (PWH) on antiretroviral therapy (ART). The study will leverage three unique cohorts to perform the first-in-human investigations directly quantifying MA concentrations in...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This $1,210,300 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel polyvalent HIV vaccines designed to prevent intravenous transmission in people who inject drugs (PWID). The research team at Beth Israel Deaconess Medical Center, Inc. (BIDMC) will create diverse HIV envelope-based vaccines and evaluate their ability to rapidly clear multiple viral strains in animal models, with...
This $196,350 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Yale University. The grant will fund a project titled "HIV COMPLEX CAUSAL MODELING: GUT MICROBIOME, DRUG USE, AND IMMUNE RESPONSES" from August 1, 2024 to July 31, 2026. The project aims to elucidate the causal relationship between drug use disorders, HIV acquisition, gut microbiome, and immune responses using Mendelian randomization...
This $780,853 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research at the University of Pittsburgh examining the impact of a glucagon-like peptide-1 receptor agonist on SIV/HIV pathogenesis and antiretroviral therapy (ART) in people living with HIV. Key objectives include assessing changes to T-cell and macrophage metabolism, immune...
The National Institute on Drug Abuse (NIDA) awarded a $1,465,275 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Alabama at Birmingham (UAB). The grant, with a project period from May 1, 2025 to March 31, 2030, will support research on the role of HIV proteins in psychostimulant abuse. The research aims to investigate how HIV proteins, such as the trans-activator of transcription (Tat) protein, can alter the molecular actions and behavioral...
This federal Project Grant award, totaling $2,812,966.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research investigating the impacts of drug abuse-mediated inflammatory perturbations on the affinity maturation of anti-CD4 autoantibodies and poor immune reconstitution from antiretroviral therapy (ART) in individuals with HIV. Specifically, the research aims to determine the mechanisms of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,940,518 to Wake Forest University Health Sciences (WFUHS) to conduct a randomized controlled trial (RCT) investigating neuroimmune mechanisms linking psychosocial stress, stimulant use, and depression in people living with HIV (PWH). The study aims to (1) examine the impact of a positive affect intervention (ARTEMIS) on neural...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $4,366,195.00 to the University of Alabama at Birmingham (UAB) to conduct a placebo-controlled, randomized clinical trial. The trial will assess the ability of the drug metformin to mitigate inflammation and improve vaccine responses in people with a history of injection drug use, including those with and without HIV. The study aims to determine metformin's impact on systemic and mucosal inflammation, B cell function, and adaptive immune responses to pathogens like hepatitis A/B and pneumococcus. The research seeks to provide insights relevant to HIV prevention and pathogenesis. The award period runs from September 30, 2024 to May 31, 2029.